Randomized clinical trial to assess the impact of oral intervention with cetylpyridinium chloride to reduce salivary SARS‐CoV‐2 viral load.

Aim: Aerosols released from the oral cavity help spread the SARS‐CoV‐2 virus. The use of a mouthwash formulated with an antiviral agent could reduce the viral load in saliva, helping to lower the spread of the virus. The aim of this study was to assess the efficacy of a mouthwash with 0.07% cetylpyridinium chloride (CPC) to reduce the viral load in the saliva of Coronavirus disease 2019 (COVID‐19) patients. Materials and Methods: In this multi‐centre, single‐blind, randomized, parallel group clinical trial, 80 COVID‐19 patients were enrolled and randomized to two groups, namely test (n = 40) and placebo (n = 40). Saliva samples were collected at baseline and 2 h after rinsing. The samples were analysed by reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) and an enzyme‐linked immunosorbent assay test specific for the nucleocapsid (N) protein of SARS‐CoV‐2. Results: With RT‐qPCR, no significant differences were observed between the placebo group and the test group. However, 2 h after a single rinse, N protein concentration in saliva was significantly higher in the test group, indicating an increase in lysed virus. Conclusions: The use of 0.07% CPC mouthwash induced a significant increase in N protein detection in the saliva of COVID‐19 patients. Lysis of the virus in the mouth could help reduce the transmission of SARS‐CoV‐2. However, more studies are required to prove this. [ABSTRACT FROM AUTHOR]